Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

USC purchases WaferGen SmartChip system for Molecular Pathways and Drug Discovery center

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genomic analysis systems, today announced that the University of Southern California (USC) has purchased the WaferGen SmartChip system for its USC Center for Molecular Pathways and Drug Discovery to discover and validate biomarkers for pancreatic and colorectal cancer applications to expedite the development of a cancer therapy. USC purchased a solution that includes the SmartChip platform and validated gene panels for biomarker profiling.

1 Dec 2010

Keryx announces positive top-line results from Zerenex Phase 3 study for hyperphosphatemia

Keryx Biopharmaceuticals, Inc. today announced positive top-line results from the Phase 3 short-term efficacy study component of its Phase 3 registration program of Zerenex (ferric citrate), the Company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.

30 Nov 2010

Genetic screening for Lynch syndrome as cost-effective as other cancer screening procedures

Myriad Genetics, Inc. today said results from a major health economics study in Cancer Prevention Research, a journal of the American Association for Cancer Research (AACR), found that screening for inherited gene mutations in the genes that cause a major colorectal cancer syndrome called Lynch Syndrome, is both medically and cost effective.

30 Nov 2010

FDA approves Axiron topical solution CIII for testosterone replacement therapy in men

Acrux , a drug delivery company that develops and commercializes patented pharmaceutical products for global markets, and Eli Lilly Company today announced that the United States Food and Drug Administration (FDA) has approved the Axiron® topical solution CIII for testosterone replacement therapy in men. Axiron is the first testosterone topical solution approved for application via an underarm applicator.

29 Nov 2010

Spectrum's FUSILEV sNDA accepted by FDA for review

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the complete response regarding its supplemental New Drug Application (sNDA) for FUSILEV® (levoleucovorin) for Injection for treatment of patients with advanced metastatic colorectal cancer.

29 Nov 2010

Dendritic cell vaccine induces immune responses in patients

A new process for creating a personalized vaccine may become a crucial tool in helping patients with colorectal cancer develop an immune response against their own tumors. This dendritic cell (DC) vaccine, developed at Dartmouth and described in a research paper published this week in the journal Clinical Cancer Research, was used after surgical resection of metastatic tumors to try to prevent the growth of additional metastases.

25 Nov 2010

Cancers detected late leading to unnecessary deaths: Report

A new report released Wednesday by the U.S. Centers for Disease Control and Prevention (CDC) says that in spite of the widely available screening tests many cancers are not diagnosed until the disease is well-advanced and, therefore, less treatable and more fatal. The report says that half of colorectal cancers and cervical cancers and one-third of breast cancers in the United States are detected at a late stage.

24 Nov 2010

New Colorectal Cancer Screening program in Quebec

On behalf of the Colorectal Cancer Association of Canada, I would like to thank Minister Bolduc and the Ministère de la Santé et des Services Sociaux for taking the first steps to implement the Colorectal Cancer Screening program in Quebec.

24 Nov 2010

Erbitux development program featured in ASCO's Clinical Cancer Advances report for third consecutive year

For the third year in a row, the American Society of Clinical Oncology (ASCO) has included Erbitux® (cetuximab) research in its annual report, Clinical Cancer Advances, which features the most significant studies of 2010. The report cites as a notable advance this year the finding that BRAF mutation status is a prognostic, not predictive, marker for Erbitux efficacy in metastatic colorectal cancer (mCRC).

23 Nov 2010

Ontario Cancer Plan third edition to address growing needs

The third edition of the Ontario Cancer Plan (OCP) ensures our cancer system serves the changing and growing needs of Ontarians. The Cancer Plan outlines priorities for cancer services, sets a course to transform cancer services from the patient perspective, and is driven by a commitment to quality across the cancer journey - from prevention to survivorship or palliative care - as the most effective way to manage cancer.

23 Nov 2010

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced results from a Phase 1b clinical trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, in patients with advanced gastrointestinal (GI) cancers.

19 Nov 2010

GWCI join forces with Banca Civica to fight cancer in Washington, D.C.

The GW Cancer Institute at The George Washington University Medical Center has joined forces with Banca Civica, a financial institution from Spain pioneering the innovative concept of civic banking, to fight cancer in Washington, D.C.

19 Nov 2010

Yorkshire scientist wins national medical award for surgical improvement in colon cancer

A Yorkshire Cancer Research scientist has earned himself a national medical award for helping pioneer life-saving surgical improvements to the way tumours are removed from colon cancer patients.

18 Nov 2010

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

A new drug that targets proteins responsible for helping cancer cells to repair damage to their DNA has shown promising anti-tumour activity in its first trial in humans.

18 Nov 2010

USPTO issues patent to Neogenix’s 16C3 monoclonal antibody for colorectal, pancreatic cancer

Neogenix Oncology, Inc. announced today that the U.S. Patent and Trademark Office (USPTO) has issued patent number 7,829,678 B2, with claims relating to 16C3 antibody, the company's monoclonal antibody for colorectal and pancreatic cancer.

17 Nov 2010

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated patient enrollment in an open-label, multi-center Phase 1b clinical trial evaluating tivozanib in combination with oral capecitabine (Xeloda®) in patients with certain advanced solid tumors.

17 Nov 2010

Risk reduction of 20 ailments with regular exercise: Review

In a review article researchers have concluded that regular exercise cuts the risk of more than 20 illnesses. Some of these include colon cancer, heart disease, diabetes, osteoporosis and stroke said the study published in the International Journal of Clinical Practice.

16 Nov 2010

Urgent need for bowel cancer screening funding

Bowel Cancer Foundation chairman, Graham Newstead feeling frustrated at the federal government’s indecision on bowel cancer screening funds has expressed his dismay. He suggested that the government should ensure the future funding for the screening test that has saved an estimated 11,000 lives since screening was introduced in 2006.

16 Nov 2010

Medicare open enrollment period starts today

Coming changes to Medicare will benefit some recipients but will make coverage more expensive for people with higher incomes. Thanks in part to this year's health care overhaul, everything from benefits and enrollment rules to the number of choices available will be affected beginning Jan. 1.

16 Nov 2010

Men treated with hormone-based therapy for prostate cancer face higher risk of colorectal cancer: Study

Men treated with hormone-based therapy for prostate cancer faced a 30 percent to 40 percent higher risk of colorectal cancer, compared to patients who did not receive this treatment, according to a new study.

16 Nov 2010

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

USC purchases WaferGen SmartChip system for Molecular Pathways and Drug Discovery center

Keryx announces positive top-line results from Zerenex Phase 3 study for hyperphosphatemia

Genetic screening for Lynch syndrome as cost-effective as other cancer screening procedures

FDA approves Axiron topical solution CIII for testosterone replacement therapy in men

Spectrum's FUSILEV sNDA accepted by FDA for review

Dendritic cell vaccine induces immune responses in patients

Cancers detected late leading to unnecessary deaths: Report

New Colorectal Cancer Screening program in Quebec

Erbitux development program featured in ASCO's Clinical Cancer Advances report for third consecutive year

Ontario Cancer Plan third edition to address growing needs

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

GWCI join forces with Banca Civica to fight cancer in Washington, D.C.

Yorkshire scientist wins national medical award for surgical improvement in colon cancer

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

USPTO issues patent to Neogenix’s 16C3 monoclonal antibody for colorectal, pancreatic cancer

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

Risk reduction of 20 ailments with regular exercise: Review

Urgent need for bowel cancer screening funding

Medicare open enrollment period starts today

Men treated with hormone-based therapy for prostate cancer face higher risk of colorectal cancer: Study

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in